Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1 clinical trials
Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis

The influence of personalized dosing on pharmacokinetics will be monitored. Furthermore, personalized extended interval dosing will be studied in a subgroup with the aim to explore lower than previously studied trough values of natalizumab.

extended interval dosing
natalizumab
progressive multifocal leukoencephalopathy
white matter disease
relapsing multiple sclerosis
  • 0 views
  • 19 Feb, 2024